Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 09/30/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.55% | 46.84% | 17.83% | 1.93% | 147.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.63% | 65.43% | -15.72% | -41.91% | -50.77% |
| Operating Income | -85.63% | -65.43% | 15.72% | 41.91% | 50.77% |
| Income Before Tax | -54.31% | -15.08% | 4.14% | 29.88% | 30.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.31% | -6.36% | 4.14% | 29.88% | 24.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.31% | -6.36% | 4.14% | 29.88% | 24.65% |
| EBIT | -85.63% | -65.43% | 15.72% | 41.91% | 50.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 87.91% | 91.18% | 10.38% | 34.53% | 22.29% |
| Normalized Basic EPS | 87.72% | 91.03% | 10.61% | 34.48% | 28.44% |
| EPS Diluted | 87.91% | 91.18% | 10.38% | 34.53% | 22.29% |
| Normalized Diluted EPS | 87.72% | 91.03% | 10.61% | 34.48% | 28.44% |
| Average Basic Shares Outstanding | 1,123.67% | 1,123.67% | 6.74% | 6.97% | -3.01% |
| Average Diluted Shares Outstanding | 1,123.67% | 1,123.67% | 6.74% | 6.97% | -3.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
